Effect and Safety of Guanxinning Tablet (冠心宁片) for Stable Angina Pectoris Patients with Xin (Heart)-Blood Stagnation Syndrome: A Randomized, Multicenter, Placebo-Controlled Trial
To investigate the effect and safety of Guanxinning Tablet (冠心宁片, GXN) for the treatment of stable angina pectoris patients with Xin (Heart)-blood stagnation syndrome (XBSS).
One hundred and sixty stable angina pectoris patients with XBSS were randomly assigned to receive GXN (80 cases) or placebo (80 cases, Guanxinning simulation tablets, mainly composed of lactose), 4 tablets (0.38 g/tablet), thrice daily for 12 weeks. After treatment, an exercise stress test (treadmill protocol), Chinese medicine (CM) syndrome score, electrocardiogram (ECG), and nitroglycerin withdrawal rate were evaluated and compared in the patients between the two groups. Meanwhile, adverse events (AEs) were evaluated during the whole clinical trial.
Compared with the control group, the time extension of exercise duration in the GXN group increased 29.28 ±17.67 s after treatment (P>0.05); moreover, the change of exercise duration in the GXN group increased 63.10 ±96.96 s in subgroup analysis (P<0.05). The effective rates of angina pectoris, CM syndrome and ECG as well as nitroglycerin withdrawal rate were 81.33%, 90.67%, 45.76%, and 70.73%, respectively in the GXN group, which were all significantly higher than those in the control group (40.58%, 75.36%, 26.92%, 28.21%, respectively, P<0.05).
GXN was a safe and effective treatment for stable angina pectoris patients with XBSS at a dose of 4 tablets, thrice daily.
KeywordsGuanxinning Tablet coronary heart disease stable angina pectoris Xin (Heart)-blood stagnation syndrome Chinese medicine
Unable to display preview. Download preview PDF.
The authors would like to thank the staff at the Xiyuan Hospital of China Academy of Chinese Medical Sciences, Jilin Integrated Chinese and Western Hospital, Affiliated Hospital of Changchun University of Chinese Medicine, Hubei Provincial Hospital of Traditional Chinese Medicine, Affiliated Hospital of Inner Mongolia University for the Nationalities and Shanghai Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, for their invaluable help in conducting this study.
- 2.Shang H, Zhang J, Yao C, Liu B, Gao X, Ren M, et al. Qi-shen-yi-qi Dripping Pills for the secondary prevention of myocardial infarction: a randomised clinical trial. Evid Based Complement Alternat Med 2013;2013:738391.Google Scholar
- 3.Lin XJ, Chai JG, Dai JM, Shi XP, Shen Y, Zhang WJ. A method and application for establishing the fingerprint of Guanxinning Tablet 2017;CN105158352B.Google Scholar
- 4.Chen ML, Wang H, Lin L, Shou QY, Zhou WM, Wang DJ, et al. Effect of Guanxinning Tablet on hemorrheology in aged rats. Lab Anim Comparat Med (Chin) 2006;26:231–233.Google Scholar
- 5.Pan YM, Ying HZ, Chen ML, Xu JQ, Zhou WM, Wang H, et al. Effects of Guanxinning Tablet on myocardial oxygen consumption in dogs. Lab Anim Comparat Med (Chin) 2007;27:190–191.Google Scholar
- 6.Wang ML, Pan YM, Jin M, Xu XP, Wang DJ, Ma QX, et al. Establishment of a zebrafish model of thrombosis and the intervention effect of Guanxinning Tablet. Acta Lab Anim Sci Sin (Chin) 2016;24:432–438.Google Scholar
- 7.The Society of Cardiovascular, Chinese Medical Association. Guidelines for the diagnosis and treatment of chronic stable angina pectoris. Chin J Cardiol (Chin) 2007;35:195–205.Google Scholar
- 11.Association CM. Guideline for diagnosis and treatment of patients with chronic stable angina. Chin J Cardiol (Chin) 2007;35:195–206.Google Scholar
- 12.Wang YZ, Wang J, Huang Q. Application of subgroup analysis in drug clinical trial. Chin J Clin Pharmacol (Chin) 2012;28:477–480.Google Scholar
- 13.Zheng XY, ed. Guiding principle of clinical research on new drugs of traditional Chinese medicine. Beijing: China Medic-Pharmaceutical Sciences and Technology Publishing Press;2002:77–80.Google Scholar
- 14.State Food and Drug Administration. Traditional Chinese medicine, natural medicine treatment of coronary heart disease angina pectoris clinical trials technical guiding principles. Available at http://www.nmpa.gov.cn/WS04/CL2196/323849.html.
- 15.Chinese Association of the Integration of Traditional and Western Medicine. Diagnostic criteria of blood-stasis symptom-complex. Chin J Integr Tradit West Med (Chin) 1987;7:129.Google Scholar
- 17.Shi ZW. Introduction and explanation of the Chinese 2007 guidelines on the diagnosis and treatment of chronic stable angina. Pract J Clin Med (Chin) 2008;5:7–9.Google Scholar
- 18.He J, Zhu HB, Zheng JH. Meta-analysis of clinical research literature on method of promoting blood circulation and removing blood-stasis for treatment of coronary heart disease. J Pract Tradit Chin Int Med (Chin) 2014;28:1–5.Google Scholar
- 20.Wu JR, Zhang XM, Zhang B, Zhai MD, Sheng XG. Systematic evaluation on Danshen Chuanxiongqin Injection in the treatment of angina pectoris. Chin J Inf Tradit Chin Med (Chin) 2015;22:39–43.Google Scholar
- 22.Jia Y, Leung SW, Lee MY, Cui G, Huang X, Pan F. The efficacy of Guanxinning Injection in treating angina pectoris: systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med 2013;2013:282707.Google Scholar
- 23.Cheng XL, Yan XT, Tu ZL, Xiao MS, Wang XT, Luo DQ. Protective effect of Guanxinning Injection on myocardial ischemia reperfusion injury in rats and effect on heat shock protein 70 expression. Chin J Hosp Pharm (Chin) 2009;29:1080–1082.Google Scholar
- 24.Chen ML, Shou QY, Pan YM, Zhang JB, Sang R, Guan MW, et al. Inhibitive and protective effects of Guanxinning Tablets on platelet aggregation and vascular endothelium in qi stagnation and blood stasis rats. Chin J Clin Pharm Therap (Chin) 2005;10:586–589.Google Scholar